Pharmacological interventions for the treatment of insomnia: quantitative comparison of drug efficacy.


Journal

Sleep medicine
ISSN: 1878-5506
Titre abrégé: Sleep Med
Pays: Netherlands
ID NLM: 100898759

Informations de publication

Date de publication:
08 2020
Historique:
received: 22 10 2019
revised: 10 02 2020
accepted: 23 03 2020
pubmed: 17 6 2020
medline: 22 6 2021
entrez: 17 6 2020
Statut: ppublish

Résumé

Although different forms of pharmacological intervention are often prescribed for insomnia disorder, the comparative efficacies among various drugs remain unclear. We therefore conducted this study to quantitatively compare the efficacy of various pharmacotherapies for insomnia by modeling. We searched PubMed, EMBASE and Cochrane Library databases for randomized placebo-controlled trials of insomnia medications that were conducted within a designated time period (from the inception dates to May 16, 2019). Pharmacodynamic models were established to describe the time course of changes from baseline in selected sleep parameters. Sleep quality and dropout rates were also compared by a single-arm meta-analysis. In sum, 43 studies covering 44 trials (14,535 patients) were included in the analysis. The drugs evaluated included flurazepam, quazepam, temazepam, triazolam, eszopiclone, zaleplon, zolpidem, extended-release zolpidem, suvorexant, ramelteon and doxepin. The established models revealed eszopiclone had the highest efficacy in terms of sleep latency (SL), total sleep time (TST), and sleep quality, and was also associated with the lowest dropout rates. The effect of suvorexant on the parameter 'wake after sleep onset' (WASO) was significantly higher than that of the other drugs analyzed. Each drug has its own characteristics in the treatment of insomnia, and this needs to be taken into consideration to meet individual clinical needs. These results serve as a quantitative supplement for clinical practice by reflecting the difference in efficacy of various drugs in the treatment of insomnia.

Identifiants

pubmed: 32544795
pii: S1389-9457(20)30141-6
doi: 10.1016/j.sleep.2020.03.022
pii:
doi:

Substances chimiques

Hypnotics and Sedatives 0
Pharmaceutical Preparations 0
Zolpidem 7K383OQI23
Eszopiclone UZX80K71OE

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

41-49

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Xijun Zheng (X)

Center for Drug of Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Yingchun He (Y)

Center for Drug of Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Fang Yin (F)

Center for Drug of Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Hongxia Liu (H)

Center for Drug of Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Yunfei Li (Y)

Center for Drug of Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Qingshan Zheng (Q)

Center for Drug of Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Electronic address: qingshan.zheng@drugchina.net.

Lujin Li (L)

Center for Drug of Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Electronic address: lilujin666@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH